Immuron to present at the Military Health System Research Symposium
14 Agosto 2023 - 7:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce that it will be presenting at The Military Health System
Research Symposium (MHSRS), in Kissimmee, Florida from the 14th to
the 17th of August 2023.
The MHSRS is the U.S. Department of Defense’s
premier scientific meeting that focuses specifically on the unique
medical needs of the Warfighter. This annual symposium brings
together nearly 3,000 healthcare professionals, researchers, U.S
DoD leaders and decision markers as well as various funding bodies
and will be a good networking opportunity for the company.
The company will attend the meeting as an
Exhibitor and present two posters at the event. One entitled
‘Clinical Evaluation of an Oral prophylactic for prevention of
Travelers diarrhea in active-duty military assigned abroad’. The
company has also been invited by the Medical Technology Enterprise
Consortium (MTEC) to showcase Immuron and its collaborative work
with the U.S. Department of Defence including an overview of the
current MTEC award entitled ‘Biologics licence application of a
bovine immunoglobulin supplement that prevents travelers’ diarrhea
caused by enterotoxigenic Escherichia coli (ETEC)’.
The Naval Medical
Research Center (NMRC) are also presenting a poster at the
symposium on the new oral therapeutic targeting Campylobacter and
Enterotoxigenic Escherichia coli (ETEC) developed in collaboration
with Immuron. The NMRC poster is entitled ‘Research and Development
of Hyperimmune Bovine Colostrum Products for the Prevention of
Travelers’ Diarrhea’.
Copies of the presentations are available on the
Company’s website.
https://www.immuron.com.au/product-science/
Infectious diarrhea is the most common illness
reported by travelers visiting developing countries and among US
troops deployed overseas. The morbidity and associated discomfort
stemming from diarrhea decreases daily performance, affects
judgment, decreases morale and declines operational readiness. The
first line of treatment for infectious diarrhea is the prescription
of antibiotics. Unfortunately, in the last decade, several enteric
pathogens have demonstrated increasing resistance to commonly
prescribed antibiotics. In addition, travelers' diarrhea is now
recognized by the medical community to result in post-infectious
sequelae, including post-infectious irritable bowel syndrome (IBS)
and several post-infectious autoimmune diseases. A preventative
treatment that defends against infectious enteric diseases is a
high priority objective for the US Military.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven LydeamoreChief Executive
OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
|
|
|
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immuron (NASDAQ:IMRN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024